Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This will be an open label study to assess the influence of renal impairment on the
pharmacokinetics (PK) of GLPG0634 and its metabolite after once daily oral administrations of
100 mg GLPG0634 for 10 days in subjects with renal impairment and matched healthy controls.
Also, safety and tolerability of once daily oral doses of GLPG0634 for 10 days in subjects
with renal impairment and matched healthy controls will be evaluated.